| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Tomatidine is a potent inhibitor of Staphylococcus aureus small-colony variants, also acting as an anti-inflammatory agent by blocking NF-κB and JNK signaling.
| ln Vitro |
Tomatidine inhibits NF-κB nuclear translocation, JNK activation, and I-κBα phosphorylation, which in turn inhibits c-jun phosphorylation and Oct-2 expression, hence reducing inducible NO synthase and COX-2 expression. At 40 μM, the formation of nitrite was suppressed by 66%, 22%, and 41% of tomate, solanine, and diosgenin, respectively. Tomatine generated a dose-dependent suppression of LPS-induced iNOS expression, and iNOS protein was hardly detectable in unstimulated cells but rose considerably following LPS treatment. Since p65 is a key component of NF-κB in LPS-stimulated macrophages, it was determined how tomatidine affected p65's ability to bind DNA. A dose-dependent inhibition of NF-κB binding activity was observed at tomatine doses of 10–40 μM. Tomatidine suppresses I-κB phosphorylation, prevents I-κB synthesis, and further suppresses the translocation of p65 NF-κB to the nucleus, controlling binding activity [1].
|
|---|---|
| References | |
| Additional Infomation |
Tomatidine is a 3beta-hydroxy steroid resulting from the substitution of the 3beta-hydrogen of tomatidane by a hydroxy group. It is an azaspiro compound, an oxaspiro compound and a 3beta-hydroxy steroid. It is a conjugate base of a tomatidine(1+). It derives from a hydride of a tomatidane.
Tomatidine has been reported in Solanum tuberosum, Solanum kieseritzkii, and other organisms with data available. |
| Molecular Formula |
C27H45NO2
|
|---|---|
| Molecular Weight |
415.66
|
| Exact Mass |
415.345
|
| CAS # |
77-59-8
|
| Related CAS # |
Tomatidine hydrochloride;6192-62-7
|
| PubChem CID |
65576
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
527.2±25.0 °C at 760 mmHg
|
| Melting Point |
210.5℃
|
| Flash Point |
272.7±23.2 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.560
|
| LogP |
6.15
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
30
|
| Complexity |
696
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C[C@H]1CC[C@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O)C)C)C)NC1
|
| InChi Key |
XYNPYHXGMWJBLV-VXPJTDKGSA-N
|
| InChi Code |
InChI=1S/C27H45NO2/c1-16-7-12-27(28-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(29)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28-29H,5-15H2,1-4H3/t16-,17-,18-,19-,20+,21-,22-,23-,24-,25-,26-,27-/m0/s1
|
| Chemical Name |
(1R,2S,4S,5'S,6S,7S,8R,9S,12S,13S,16S,18S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-piperidine]-16-ol
|
| Synonyms |
5alpha-Tomatidan-3beta-ol Tomatidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~40.11 mM)
0.1 M HCL :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.29 mg/mL (0.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 2.9 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.29 mg/mL (0.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 2.9 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.29 mg/mL (0.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5 mg/mL (12.03 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4058 mL | 12.0291 mL | 24.0581 mL | |
| 5 mM | 0.4812 mL | 2.4058 mL | 4.8116 mL | |
| 10 mM | 0.2406 mL | 1.2029 mL | 2.4058 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
